Pricing
  1. JP-listed companies
  3. Financials
  4. Capital expenditures

【JP:206A】

Market cap
¥6.7B
P/E ratio
PRISM BioLab develops new drugs that target hard-to-reach protein interactions inside cells, partnering with major pharmaceutical companies like Eisai.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndCapital expenditures (Million JPY)YoY (%)
Sep 30, 2025-65-68.56%
Sep 30, 2024-206+494.95%
Sep 30, 2023-35+505.02%
Sep 30, 2022-6

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)